Phase 2a multi-national study of TCMCB07 in pancreatic cancer
Latest Information Update: 25 Apr 2024
At a glance
- Drugs TCMCB 07 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
Most Recent Events
- 23 Apr 2024 According to an Endevica Bio media release, the company will entering Phase 2 studies this summer.
- 01 Jul 2022 New trial record
- 28 Jun 2022 According to an Endevica Bio media release, the company is finalizing the protocol and expect to initiate this trial in 2Q 2023.